Cellectis names new chief medical officer

Allogeneic CAR T-cell therapies specialist Cellectis (Alternext: ALCLS) has announced the appointment of Loan Hoang-Sayag to the role of chief medical officer.

Dr Hoang-Sayag’s responsibilities will include bringing the company's product candidates into clinical-stage development, as well as strategic and operational management of all therapeutic activities for Cellectis. She joins Cellectis from Quintiles Transnational, where she was most recently senior director of medical science.

“Dr Hoang-Sayag’s experience in oncology clinical development – specifically in strategy and delivery in all phases in the pharmaceutical, biotechnology and clinical research spaces – enables her to lead Cellectis’ strategy and generate awareness around the breakthrough work that we are doing as a leader and innovator in the field,” said André Choulika, chairman and chief executive of Cellectis. “Her relationship-building and communication skills, deep understanding of the global environment in oncology clinical research and close relationships with regulatory and business development units add a high caliber of talent and depth to our current leadership team. This will be extremely beneficial as Cellectis continues to build upon its brand and expand our product candidates into clinical stage development,” Dr Choulika added.